A Phase I Study of the Combination of Carboplatin, Docetaxel, and Increasing Doses of Sublingual Anvirzel (Nerium Oleander) in Advanced Non-Small Cell Lung Cancer

Trial Profile

A Phase I Study of the Combination of Carboplatin, Docetaxel, and Increasing Doses of Sublingual Anvirzel (Nerium Oleander) in Advanced Non-Small Cell Lung Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2015

At a glance

  • Drugs Nerium oleander extract (Primary) ; Carboplatin; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Most Recent Events

    • 05 Jun 2015 Status changed from active, no longer recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov record.
    • 20 Aug 2013 Planned End Date changed from 1 Apr 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 20 Aug 2013 Planned number of patients changed from 30 to 36 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top